enGene Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Jul '26 Jul 8, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Dec '22 Dec 31, 2022	Oct '22 Oct 31, 2022
Market Cap	125	375	451	-	-	-
Market Cap Growth	-22.60%	-16.87%	-	-	-	-
Enterprise Value	-100.51	213.04	237.76	0	0	0
Last Close Price	1.86	7.21	8.85	-	-	-
PE Ratio	-	3.15	6.06	-	-	-
PB Ratio	0.49	2.24	1.65	-	-	-
P/TBV Ratio	0.44	2.20	1.23	-	-	-
Debt / Equity Ratio	0.12	0.13	0.09	0.13	-1.15	-1.15
Net Debt / Equity Ratio	-0.88	-0.97	-0.78	-0.99	-0.10	-0.10
Net Debt / EBITDA Ratio	1.71	1.32	3.44	2.78	-	-0.41
Net Debt / FCF Ratio	2.02	1.61	4.34	2.87	-	-0.44
Quick Ratio	12.07	6.09	16.28	15.97	4.28	4.28
Current Ratio	12.57	6.30	16.87	16.25	4.42	4.42
Return on Equity (ROE)	-59.99%	-53.28%	-31.96%	-407.91%	0.00%	208.22%
Return on Assets (ROA)	-50.02%	-46.25%	-31.28%	-47.02%	0.00%	-162.65%
Return on Invested Capital (ROIC)	-383.70%	-379.44%	-207.94%	-267.71%	0.00%	-103.40%
Return on Capital Employed (ROCE)	-55.76%	-50.69%	-32.94%	-51.86%	0.00%	-206.61%
Earnings Yield	-	31.76%	16.50%	-	-	-
Buyback Yield / Dilution	-25.52%	-35.30%	-5355.07%	-4.03%	-1.62%	-
Total Shareholder Return	-25.52%	-35.30%	-5355.07%	-4.03%	-1.62%	-

SEC Filings: 10-K · 10-Q